期刊文献+

5-氟尿嘧啶在小鼠结肠癌模型中的药效与毒性评价研究 被引量:4

Efficacy and Toxicity of 5-Fluorouracil in Colon Cancer Treatment of a Mouse Syngeneic Model
下载PDF
导出
摘要 为探讨5-氟尿嘧啶的药效、毒性与给药剂量之间的关系,采用BALB/c小鼠来源的CT26结肠癌细胞株构建小鼠结肠癌模型,分别给予10、20、30和50 mg/kg剂量的5-氟尿嘧啶,分析其抗肿瘤效果、对小鼠体质量的影响和死亡率等指标.结果表明,5-氟尿嘧啶的体内抑瘤效果及毒性与剂量密切相关.综合分析评价各指标,认为20~30 mg/kg剂量的5-氟尿嘧啶较适合于小鼠结肠癌模型中的药效评价. To investigate the relationship of anticancer effects, toxicity and dose, tumor syngeneic models were made from murine colorectal adenocarcinoma cell line CT26 derived from BALB/c mice. Mice were treated with various doses (10, 20, 30 and 50 mg/kg) of 5-fluorouracil (5-FU), and the indexes were analyzed, including the anti-tumorigenic effects, body mass and mortality of mice. The results showed that the efficacy and toxicity of 5-FU was closely related to the doses, and the proposal dose was 20 -30 mg/kg which may be the optimal dose for drug research in tumor syngeneic model of mice.
出处 《华南农业大学学报》 CAS CSCD 北大核心 2012年第4期535-538,共4页 Journal of South China Agricultural University
基金 The Public Welfare & Safety Research Program through the National Research Foundation of Korea(NRF)funded by the Ministry of Education Science and Technology(2011-0020967) 国家自然科学基金(31001117)
关键词 5-氟尿嘧啶 药效 毒性 结肠癌 5-fluorouracil efficacy toxicity colon cancer
  • 相关文献

参考文献1

二级参考文献12

  • 1A. Mantovani,P. Allavena,A. Vecchi,S. Sozzani,A. Mantovani.Chemokines and chemokine receptors during activation and deactivation of monocytes and dendritic cells and in amplification of Th1 versus Th2 responses[J].International Journal of Clinical & Laboratory Research.1998(2)
  • 2Emi Nakashima,Akiko Oya,Yuri Kubota,Naomi Kanada,Ryo Matsushita,Kazuyoshi Takeda,Fujio Ichimura,Kouji Kuno,Naofumi Mukaida,Kunitaka Hirose,Isao Nakanishi,Toshimitsu Ujiie,Kouji Matsushima.A Candidate for Cancer Gene Therapy: MIP-lα Gene Transfer to an Adenocarcinoma Cell Line Reduced T\imorigenicity and Induced Protective Immunity in Immunocompetent Mice[J].Pharmaceutical Research.1996(12)
  • 3Emtage PC,Wan Y,Hitt M,et al.Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models[].Human Gene Therapy.1999
  • 4Adams DH,Lloyd AR.Chemokines:leucocyte recruitment and activation cytokines[].The Lancet.1997
  • 5Miyata T,Yamamoto S,Sakamoto K,et al.Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector,HVJ cationic liposomes[].Cancer Gene Therapy.2001
  • 6Sozzani S,Allavena P,D’Amico G,et al.Differential regulation of chemokine receptors during dendritic cell maturation:a model for their trafficking properties[].J Immunol.1998
  • 7Lin CL,Suri RM,Rahdon RA,et al.Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation[].European Journal of Immunology.1998
  • 8Sallusto E Mackay CR.The role of chemokine receptors in primary,effector,and memory immune responses[].Annual Review of Immunology.2000
  • 9Rollins BJ.Chemokines[].Blood.1997
  • 10Xu LL,Warren MK,Rose WL,et al.Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro[].Journal of Leukocyte Biology.1996

共引文献7

同被引文献43

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部